Clinical Trial VICCTHN1257


A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy followed by Standard Chemoradiation/Afatinib in HPV Negative Locally Advanced Stage III/IVa/IVb HNSCC

Principal Investigator(s)

Jill Gilbert


  • Protocol No. VICCTHN1257
  • Open Date: 08/30/2013
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the safety of 30mg once daily oral afatinib in combination with carboplatin AUC 6 and Paclitaxel 175mg/m2 q 21 days as an induction regimen in patients with HPV negative , AJCC stage III and IVa and IVb HNSCC of oral cavity, oropharynx, hypopharynx, and larynx.
  • Disease Sites: Head/Neck
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics; Radiotherapy
  • Drugs: Afatinib; Carboplatin; Cisplatin; Paclitaxel
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01732640
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.